ES2111304T3 - Composicion de administracion por via nasal de un medicamento que contiene nicotina. - Google Patents

Composicion de administracion por via nasal de un medicamento que contiene nicotina.

Info

Publication number
ES2111304T3
ES2111304T3 ES94915637T ES94915637T ES2111304T3 ES 2111304 T3 ES2111304 T3 ES 2111304T3 ES 94915637 T ES94915637 T ES 94915637T ES 94915637 T ES94915637 T ES 94915637T ES 2111304 T3 ES2111304 T3 ES 2111304T3
Authority
ES
Spain
Prior art keywords
nicotine
ion
compound
nasal administration
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915637T
Other languages
English (en)
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Application granted granted Critical
Publication of ES2111304T3 publication Critical patent/ES2111304T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Diffracting Gratings Or Hologram Optical Elements (AREA)
  • Lasers (AREA)
  • Optical Couplings Of Light Guides (AREA)
  • Optical Filters (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN COMPUESTO PARA MEDICAMENTO DE ADMINISTRACION NASAL CON CONTENIDO EN NICOTINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE, O UN DERIVADO DE LA MISMA EN EL QUE EL COMPUESTO SE ADAPTA AL SUMINISTRO DE UN PULSO DE NICOTINA PARA ABSORCION RAPIDA Y DE UNA LIBERACION DE NICOTINA CONTROLADA PARA SU POSTERIOR ABSORCION SOSTENIDA. LA FASE DE SUMINISTRO CONTROLADO PUEDE LOGRARSE PROPORCIONANDO UN MATERIAL PERMUTADOR DE IONES QUE FORMARA UN COMPLEJO CON LA NICOTINA. EL MATERIAL PERMUTADOR DE IONES PUEDE SER UN MATERIAL POLIMERICO COMO LOS POLISACARIDOS, O PUEDE PRESENTARSE EN FORMA DE MICROSFERAS BIOADHESIVAS PERMUTADORAS DE IONES . LA LIBERACION DE PULSOS PUEDE LOGRARSE SOBRECARGADO EL MATERIAL PERMUTADOR DE IONES CON NICOTINA, DE FORMA QUE EL COMPUESTO TENGA UN EXCESO DE NICOTINA PARA SU INMEDIATA LIBERACION Y ABSORCION. DE FORMA ALTERNATIVA, UNA PARTE DE LA NICOTINA PUEDE ESTAR ASOCIADA CON UN MATERIAL NO PERMUTADOR DE IONES QUE LIBERARA LA NICOTINA INMEDIATAMENTE AL ENTRAR EN CONTACTO CON LA MUCOSA NASAL, COMO POR EJEMPLO LAS MICROSFERAS BIOADHESIVAS NO PERMUTADORAS DE IONES.
ES94915637T 1993-05-20 1994-05-20 Composicion de administracion por via nasal de un medicamento que contiene nicotina. Expired - Lifetime ES2111304T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310412A GB9310412D0 (en) 1993-05-20 1993-05-20 Nasal nicotine system

Publications (1)

Publication Number Publication Date
ES2111304T3 true ES2111304T3 (es) 1998-03-01

Family

ID=10735826

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915637T Expired - Lifetime ES2111304T3 (es) 1993-05-20 1994-05-20 Composicion de administracion por via nasal de un medicamento que contiene nicotina.

Country Status (14)

Country Link
US (1) US5935604A (es)
EP (1) EP0697858B1 (es)
JP (1) JPH08510467A (es)
AT (1) ATE159425T1 (es)
AU (1) AU685458B2 (es)
CA (1) CA2163089A1 (es)
DE (1) DE69406440T2 (es)
DK (1) DK0697858T3 (es)
ES (1) ES2111304T3 (es)
FI (1) FI955583L (es)
GB (2) GB9310412D0 (es)
GR (1) GR3025890T3 (es)
NO (1) NO306847B1 (es)
WO (1) WO1994027576A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP0898961A1 (de) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Pharmazeutische Zubereitung zur verbesserten Schmerztherapie bei akutem, postoperativem oder chronischem Schmerz
DE69831421T2 (de) * 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
WO2000050078A1 (en) * 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
EP1218048A4 (en) * 1999-07-16 2009-08-26 Aradigm Corp SYSTEM FOR STOPPING SMOKING
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
AT409219B (de) * 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20020176841A1 (en) * 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
PL364621A1 (en) * 2001-03-26 2004-12-13 Smithkline Beecham Corporation Nicotine-containing oral dosage form
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20040101543A1 (en) * 2002-03-22 2004-05-27 John Liu Nicotine-containing oral dosage form
US6586449B1 (en) * 2002-05-28 2003-07-01 Cambrex Charles City, Inc. Nicotine-containing, controlled release composition and method
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
PT1578422E (pt) * 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
WO2004098647A2 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins’ underexpression as markers of tumor metastasis
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
CA2533165A1 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
CN104397869B (zh) * 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
WO2005053691A2 (en) * 2003-12-02 2005-06-16 Fertin Pharma A/S Nicotine delivery product and method for producing it
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CN102164618A (zh) * 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
WO2008069970A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Nicotine formulations, kits and systems and methods for their use
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20080287507A1 (en) * 2007-05-16 2008-11-20 John Hedenstrom Nicotine containing toiletry waters
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
DK2198865T3 (da) 2008-12-19 2012-01-16 Siegfried Ltd Nikotinholdigt produkt
WO2011049960A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
US10130120B2 (en) 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
WO2016130908A1 (en) * 2015-02-13 2016-08-18 The University Of Toledo Therapeutic polysaccharide midi-gagr and related materials and methods
WO2017151651A1 (en) * 2016-02-29 2017-09-08 Belmont University Pharmaceutical in situ gelling compositions
EP3442583B1 (en) 2016-04-12 2024-04-10 Arturo Solis Herrera Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa
WO2018113916A1 (en) * 2016-12-20 2018-06-28 Fertin Pharma A/S A mucoadhesive oromucosal formulation comprising a nicotine complex
CA3085065C (en) 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
WO2019110072A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Nicotine tablet
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
WO2022132018A1 (en) * 2020-12-16 2022-06-23 Liw Innovation Ab A new powder composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making
US3655866A (en) * 1970-01-26 1972-04-11 Warner Lambert Co Sugarless gum containing dicalcium phosphate dihydrate
CA1139221A (en) * 1978-10-10 1983-01-11 Vijay B. Surpuriya Antacid compositions
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
GB2133691B (en) * 1983-01-21 1986-05-21 Leo Ab Smoking substitutes for nasal administration
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
IL73912A0 (en) * 1984-01-09 1985-03-31 Advanced Tobacco Prod Nicotine preparation
JPS6115830A (ja) * 1984-06-28 1986-01-23 ザ　プロクタ−　アンド　ガンブル　カンパニ− 制酸剤組成物およびその製造方法
US4971787A (en) * 1984-08-27 1990-11-20 Warner-Lambert Company Antacid chewing gum
US4882152A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for laxatives, vitamins and antacids
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
SE8904295D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Smoking substitute
DE4140116A1 (de) * 1991-12-05 1993-06-09 Bolder Arzneimittel Gmbh Dimeticon-pastillen
GB9200047D0 (en) * 1992-01-03 1992-02-26 Univ Alberta Nicotine-containing nasal spray
JPH09501678A (ja) * 1993-08-13 1997-02-18 ベイヤー、コーポレーション かむ錠剤の芳香増進剤としての加水分解ゼラチン
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine

Also Published As

Publication number Publication date
DK0697858T3 (da) 1998-05-04
AU6727294A (en) 1994-12-20
DE69406440T2 (de) 1998-04-02
JPH08510467A (ja) 1996-11-05
DE69406440D1 (de) 1997-11-27
GB2292316B (en) 1997-03-26
FI955583A7 (fi) 1996-01-19
FI955583A0 (fi) 1995-11-20
NO954582D0 (no) 1995-11-14
CA2163089A1 (en) 1994-12-08
NO306847B1 (no) 2000-01-03
NO954582L (no) 1995-11-14
EP0697858B1 (en) 1997-10-22
GB9523372D0 (en) 1996-01-17
GB2292316A (en) 1996-02-21
ATE159425T1 (de) 1997-11-15
US5935604A (en) 1999-08-10
GB9310412D0 (en) 1993-07-07
WO1994027576A1 (en) 1994-12-08
GR3025890T3 (en) 1998-04-30
EP0697858A1 (en) 1996-02-28
AU685458B2 (en) 1998-01-22
FI955583L (fi) 1996-01-19

Similar Documents

Publication Publication Date Title
ES2111304T3 (es) Composicion de administracion por via nasal de un medicamento que contiene nicotina.
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
MXPA04003807A (es) Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
AR033688A1 (es) Composicion parenteral reconstituible
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
ES2115638T3 (es) Composicion tiroactiva de liberacion controlada.
AU678859B2 (en) Immediate release tablet cores of insoluble drugs having sustained release coating
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2114562T3 (es) Forma de dosificacion para distribucion retardada de farmacos.
TW234691B (es)
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
ES2159569T3 (es) Procedimiento de preparacion de derivados de sufentanil por adicion de carbeno y aminolisis de 4-piperidona.
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ES2063186T3 (es) Derivados ftalinida, composicion farmaceutica y uso.
AR013163A1 (es) Uso de composiciones que contienen diclorofenil imidazoldioxolano para la preparacion de un medicamento para tratar la dermatitis seborreica, caspa,psoriasis y acne, composiciones propiamente dichas, y un articulo de fabricacion que contiene dicha composicion
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
SE8901003D0 (sv) Snabbloesliga preparat
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
IT1258143B (it) Compresse a cessione programmata contenenti naproxen
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
Tosti et al. Contact dermatitis due to chlorpheniramine maleate in eyedrops.
HUT62855A (en) Process for producing glycerol derivatives and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697858

Country of ref document: ES